Summary: Benzinga reports on MAPS’ progress towards FDA approval of MDMA-assisted psychotherapy for the treatment of PTSD. The article highlights the promising results from the Phase 3 interim analysis, the momentum of MAPS’ $10 million Capstone Challenge fundraising campaign, and how the potential FDA approval of MDMA-assisted psychotherapy for PTSD may clear the way for other psychedelics to receive approval as prescription treatments.
Originally appearing here.
